SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 103 filers reported holding SYROS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 2.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $695,000 | -63.5% | 584,272 | 0.0% | 0.01% | -58.3% |
| Q4 2021 | $1,905,000 | -27.1% | 584,272 | 0.0% | 0.01% | -33.3% |
| Q3 2021 | $2,612,000 | -18.0% | 584,272 | 0.0% | 0.02% | -18.2% |
| Q2 2021 | $3,184,000 | +81.5% | 584,272 | +245.7% | 0.02% | -4.3% |
| Q3 2019 | $1,754,000 | +12.6% | 169,000 | 0.0% | 0.02% | +21.1% |
| Q2 2019 | $1,558,000 | -16.5% | 169,000 | -17.2% | 0.02% | -20.8% |
| Q1 2019 | $1,865,000 | +64.2% | 204,000 | 0.0% | 0.02% | +41.2% |
| Q4 2018 | $1,136,000 | -53.3% | 204,000 | 0.0% | 0.02% | -46.9% |
| Q3 2018 | $2,430,000 | +16.7% | 204,000 | 0.0% | 0.03% | -3.0% |
| Q2 2018 | $2,083,000 | -21.3% | 204,000 | 0.0% | 0.03% | -26.7% |
| Q1 2018 | $2,648,000 | +29.6% | 204,000 | -2.9% | 0.04% | +28.6% |
| Q4 2017 | $2,043,000 | +15.7% | 210,000 | +75.0% | 0.04% | +12.9% |
| Q3 2017 | $1,766,000 | – | 120,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
| Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
| Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
| Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
| EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
| Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
| Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
| Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
| Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |